FMP
Aug 03, 2023(Last modified: Dec 19, 2023)
Moderna (NASDAQ:MRNA) announced second-quarter results that surpassed expectations, even though its revenue experienced a significant decline due to decreased demand for its COVID-19 vaccine after the peak of the pandemic.
Q2 total revenue for the U.S. biotech company amounted to $344 million, representing a substantial 93% drop compared to the $4.75 billion recorded during the same period last year. Despite this decline, the reported revenue still exceeded the Street estimate of $321.8 million.
As a result of the positive earnings report, Moderna's shares saw an increase of more than 2% intra-day today.

In times of rising geopolitical tension or outright conflict, defense stocks often outperform the broader market as gove...

As Circle Internet (NYSE:CRCL) gains attention following its recent public listing, investors are increasingly scrutiniz...

LVMH Moët Hennessy Louis Vuitton (OTC:LVMUY) is a global leader in luxury goods, offering high-quality products across f...